Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 9 - 12 February 2026 | European Medicines Agency (EMA) PRAC concludes safety review of levamisole, a medicine used to treat parasitic worm infections

We have just recommended that medicines containing #levamisole, used to treat parasitic worm infections, be withdrawn from the EU market due to the risk of leukoencephalopathy, a condition that affects the brain’s white matter.

Read more 🔗 www.ema.europa.eu/en/news/meet...

#PublicHealth #MedSky 🧪

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 1 – 4 September 2025 | European Medicines Agency (EMA) PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections

EMA starts a review of medicines containing #levamisole, used to treat parasitic worm infections, to assess the risk of leukoencephalopathy, a condition affecting the brain.

Find out more in the #PRAC highlights 🔍 www.ema.europa.eu/en/news/meet...

New research in #RESPhysEnt finds that dietary #levamisole induces DNA damage in the haemolymph of #Galleria mellonella
doi.org/10.1111/phen.12496

#Waxmoth #PestManagement
@wybouw.bsky.social @tbuescher.bsky.social @tobybruce.bsky.social @wiley.com